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Key Points: 
 
 Weekly and biweekly administration of panobinostat following allogeneic stem cell 
transplantation for high risk AML and MDS patients is feasible with excellent long-term 
outcome  
 Combined treatment of panobinostat with donor lymphocyte infusions is feasible without 
evidence of enhanced GvHD  
 These data provide the basis for a confirmatory prospective, randomized phase III trial in 
patients with advanced and high risk AML and MDS 
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Abstract 
Relapse is the major cause of treatment failure following allogeneic hematopoietic stem cell 
transplantation (HSCT) for acute myeloid leukemia (AML) or myelodysplastic syndromes 
(MDS). Salvage treatment with discontinuation of immunosuppression and donor lymphocyte 
infusions is rarely effective and frequently induces severe graft-versus-host disease. The 
deacetylase inhibitor (DACi) panobinostat demonstrated moderate anti-leukemic activity in 
phase I/II trials and displays a broad range of immunomodulatory functions, prompting us to 
investigate its use as post-transplant prophylaxis. Primary objective of this phase I/II trial 
(n=42 patients) was to determine the maximum tolerated dose (MTD) and dose-limiting 
toxicity (DLT) of panobinostat given after HSCT by two different schedules. The MTDs were 
20 mg TIW with weekly and 30 mg TIW with alternating week schedules, DLTs were 
gastrointestinal and constitutional. Alternating week administration was better tolerated with 
delivery of a significantly higher cumulative panobinostat dose. In these high risk patients, of 
whom 67% had active disease at the time of HSCT, survival probability at 2 years is 81% 
with a 20% cumulative rate of relapse. Panobinostat as post-HSCT maintenance therapy for 
high-risk AML and MDS is feasible with very good outcome. A prospective, randomized trial 
is needed to confirm the role of DACi maintenance after HSCT. 
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Introduction 
Relapse is the major obstacle following an allogeneic hematopoietic stem cell transplantation 
(HSCT) for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) (1), (2),  
particularly in patients with high-risk features based on adverse cytogenetics or advanced 
disease. While sequential intensive cytoreductive therapy followed by a reduced intensity 
conditioning has improved outcome compared with standard conditioning (3), (4), (5), relapse 
rate remains substantial and ranges from 30 to 60% (6), (7), (8), (9). Moreover, these 
regimens rely on a graft-versus-leukemia (GvL) effect achieved by early discontinuation of 
immunosuppression and prophylactic donor lymphocyte infusions (DLI) which frequently 
induce significant graft-versus-host disease (GvHD) (10), (11), the principal cause of ensuing 
non-relapse mortality. 
Salvage treatment for relapse after HSCT is rarely effective; in studies combining DLI with 
the hypomethylating agents azacitidine (12), (13), (14), (15), (16) or decitabine (17), 10-27% 
of patients achieved a CR and median OS is 10-15%. In contrast, azacitidine initiated pre-
emptively upon evidence of impending relapse has been more effective in delaying or 
possibly preventing overt relapse, with 40% of patients alive at 16 months (18). 
Evidence for anti-leukemic activity of the deacetylase inhibitor (DACi) panobinostat stems 
from phase I/II trials in which complete and partial responses were observed in a small 
subset of patients with relapsed or refractory AML and high-risk MDS (19), (20). In addition to 
direct antiproliferative and proapoptotic effects on leukemic cells (21), DACi exhibit diverse 
immunostimulatory and -inhibitory effects attributed to targeting of histones and non-histone 
proteins (22), (23)). In AML blasts, upregulation of major histocompatibility complex (MHC) 
class I and II molecules as well as costimulatory and adhesion molecules suggests that DACi 
may enhance leukemia-specific cytotoxicity (24), (25). A similar effect may be mediated by 
downregulation of the immune checkpoint programmed cell death protein 1 (PD1) on CD4 
and CD8 positive T cells, as observed with panobinostat treatment for Hodgkin´s lymphoma 
(26). Conversely, DACi may reduce the number of antigen presenting cells, downregulate 
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secretion of proinflammatory cytokines, increase number and suppressor function of 
regulatory T cells and impair NK cell function (27), (28), (29), effects that could potentially 
impair GvL but also be beneficial by mitigating GvHD. 
We hypothesized that on balance, panobinostat could reduce the relapse rate in patients with 
high-risk myeloid diseases while simultaneously reducing GvHD. Here, we present the 
results of the phase I/II PANOBEST trial using panobinostat as maintenance post-HSCT in 
high-risk AML and MDS patients. 
 
Methods 
Patients 
Adult patients (aged ≥ 18 years) with high-risk AML (except acute promyelocytic leukemia, 
AML M3) or MDS intermediate-2 or high-risk according to the International Prognostic 
Scoring System (IPSS), or RAEB according to the World Health Organization (WHO) 
classification who who were in complete hematologic remission following hematopoietic stem 
cell transplant (HSCT) were eligible. High-risk features for AML were defined as one or more 
of the following criteria: (i) refractory to or relapsed after at least one cycle of standard 
chemotherapy; (ii) > 10% bone marrow blasts at day 15 of the first induction cycle; (iii) 
adverse risk cytogenetics including complex karyotype (≥3 abnormalities or abnormalities of 
chromosomes 3, 5 or 7) regardless of stage; and/or (iv) secondary to MDS or radio-
/chemotherapy. All conditioning regimens except for >8 Gy total-body irradiation or >12 
mg/kg total oral busulfan dose were permitted. Patients had to be enrolled between days 60 
and 150 after HSCT. 
Key inclusion criteria included Eastern Cooperative Oncology Group performance status 
(ECOG PS) ≤2, ANC ≥1,000/μL, platelets ≥75,000/μL, adequate organ function and no active 
acute GvHD grades 2 - 4 or extensive chronic GvHD. Patients with clinical symptoms of 
central nervous system leukemia or impaired cardiac function (e.g. LVEF <45% by 
echocardiography) were excluded. Additionally, patients receiving a drug known to prolong 
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the QT interval that could not be terminated or who had received prior treatment with a DACi 
were not eligible.  
The study protocol was reviewed by the independent ethics committee at each center, and 
written informed consent was obtained from each patient prior to any screening procedures. 
The study is registered at http://clinicaltrials.gov as NCT01451268. 
 
Study Design 
This was an open-label, oligocenter phase I/II study. The primary objective of phase I was 
determination of the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of 
panobinostat for two different administration schedules (Figure 1A). Secondary objectives 
included preliminary analyses of the safety and tolerability of the two regimens. Patients were 
enrolled in escalating dose cohorts in two sequential schedules using a classical 3+3 design. 
Panobinostat was administered orally thrice weekly (TIW), either every week (schedule A) or 
every other week (schedule B) and was scheduled for up to one year. The one week on/one 
week off regimen evaluated the ability to deliver higher individual and cumulative 
panobinostat doses by avoiding excess hematologic and gastrointestinal toxicity. DLT was 
determined separately in both arms during the first 28 days of panobinostat treatment only 
and defined as grade 4 (CTCAE version 3.0) hematologic toxicity (i.e. G4 neutropenia or 
thrombopenia of >7 consecutive days or febrile neutropenia), ≥G3 non-hematologic toxicity, 
acute GvHD ≥G3 scored with modified Gluckberg criteria (30) or moderate of severe chronic 
GvHD as assessed according to the National Institutes of Health consensus criteria (31). 
In schedule A, panobinostat was started at a dose of 10 mg TIW and escalated to 30 mg 
TIW; in schedule B, dose escalation started at the MTD determined for weekly panobinostat 
(schedule A) and was given at doses of 20-40 mg TIW. Dose reductions or interruptions 
were permitted in case of any newly developed G3 non-hematologic AEs considered 
clinically relevant to the investigator or any G4 non-hematologic AEs, with a minimum 
panobinostat dose of 10 mg. Upon determination of the MTD, up to 42 patients were to be 
enrolled in the phase 2 portion and randomly assigned in a 1:1 ratio to receive panobinostat 
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at the MTD either weekly or every other week on a treatment schedule identical to that from 
phase I. Secondary objectives of phase 2 were to generate preliminary efficacy data of 
panobinostat at the MTD as measured by the probability of overall and relapse-free survival, 
cumulative incidence (CI) of hematologic relapse and death as well as acute and chronic 
GvHD at one year after HSCT. To take into account that patient enrollment was permitted 
until day 150 after HSCT, outcome measures reported actually refer to the first day of 
panobinostat dosing. Monitoring of immune cell reconstitution during panobinostat therapy 
was an exploratory objective. 
 
 
Safety and Efficacy Assessments 
Patients were monitored for safety throughout the trial and up to 28 days after the last dose 
of study treatment. Adverse events (AEs) were assessed according to the Common 
Terminology Criteria for Adverse Events (CTCAE) version 3.0. Safety evaluations included 
monitoring of hematology, blood chemistry, thyroid function test and urine, and regular 
assessment of vital signs, physical condition, body weight, ECOG PS, and cardiac 
monitoring. 
 
Flow cytometric analysis for quantification of leukocyte subsets  
Flow cytometric analysis was performed to determine cellular immune reconstitution post 
SCT in patients receiving panobinostat. Peripheral blood EDTA samples were analyzed 
within a maximum of 24 hours after collection using a FC500 5-color/ one laser flow 
cytometer (Beckman Coulter, Krefeld, Germany). Absolute cell count was calculated from the 
percentage values using a dual-platform approach. Monoclonal IgG1 and 2IgG2a antibodies 
against CD45, CD3, CD4, CD8, CD19, CD56, 2CD14, CD25# and CD127 (# from Becton 
Dickinson (BD), all others from Beckman Coulter, Immunotech, Marseille, France) were 
conjugated with fluorescein isothiocyanate (FITC), phycoerythrin (PE), phycoerythrin-Texas-
Red (ECD), phycoerythrin-cyanine-5 (PC5) and phycoerythrin-cyanine-7 (PC7) for staining. 
An automated lyse/no wash procedure with a fixation step followed by the ImmunoPrep® 
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reagent using TQ-PrepTM Workstation (Beckman Coulter, Krefeld, Germany) was performed. 
The first and second tube examined the quantity of leukocytes, lymphocytes, CD14+ 
monocytes, CD3+ T cells, CD3+CD4+ helper T cells, CD3+CD8+ cytotoxic T cells, CD56+CD3- 
NK cells and CD19+ B cells. The third panel allowed the measurement of the 
CD4+CD25++CD127dim/neg regulatory T cell amount. 
The optical alignment, fluidic stability and accuracy of the flow cytometer were tested with 
Flow Check Pro Fluorospheres (Beckman Coulter) and Immuno-Trol™ Cells daily, before 
measurements. Flow set Fluorospheres (Beckman Coulter) served to set up the 
photomultiplier tube values, weekly. Peripheral blood of healthy donors and stained Cyto-
Comp cells (Beckman Coulter) were used to compensate the fluorescence overlap.  
 
 
Statistical analysis 
Patients were evaluated on an intent-to-treat basis, all patients who received at least one 
dose of study drug were included in the analysis. DLT was defined as prolonged grade 4 
(G4) hematologic toxicity or any non-hematologic toxicity ≥G3 unrelated to disease 
progression or intercurrent illness within 28 days of the first panobinostat dose.  
 
Overall survival was estimated by the Kaplan-Meier method starting from the day of the first 
dose of panobinostat to either death or up to 30 months of follow up, whichever occurred 
first. Events for relapse-free survival were death or relapse. Cumulative incidence of relapse, 
non-relapse mortality (NRM) and chronic GvHD were estimated by the proportional hazards 
method with relapse and NRM as competing events for each other, and relapse and NRM as 
competing events for chronic GvHD. IBM SPSS  statistics version 23 and R software were 
used as statistical software. 
Longitudinal analysis of cellular reconstitution was performed using the R software for 
statistical computing, version 3.2.1 and the Linear and Nonlinear Mixed Effects Models 
(nlme) package (32). First, cells counts were logarithmically transformed in order to attain 
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residuals with normal distribution. Afterwards, mixed spline linear regression was fitted for 
each cell population and for the percentage of Treg (in % of helper T cells). The applied 
statistical method considers dependencies in the data due to repeated measures. P-values 
were considered significant for p<0.05 (*) and p<0.01 (**). 
 
 
Results 
Patients 
A total of 42 patients (37 AML, 5 MDS) with a median age of 52 (21-71) years and ECOG PS 
of either 0 (57%) or 1 (43%) were enrolled between January 2011 and January 2015. Data 
cutoff for this analysis is November 13, 2015. The majority of patients (n=28, 67%) were 
transplanted with active disease (BM blasts 0-80%, median 21%, 1 patient with isolated 
extramedullary AML), 9 in CR1 (21%) and 5 in CR2 (12%). Patient and transplant 
characteristics were equally distributed between schedules A and B and are summarized in 
table 1. 
 
Determination of maximal tolerated dose and dose limiting toxicity 
Patient disposition is outlined in figure 1B. All 12 patients in the phase 1 part of schedule A 
(10 mg, n = 3; 20 mg, n = 6; 30 mg, n = 3) and 11 of 12 patients in phase 1 of schedule B (20 
mg, n = 3; 30 mg, n = 6; 40 mg, n = 3) were evaluable for determination of MTD. Overall, 5 
DLTs were observed, three in schedule A (fatigue G3 at 20 mg, colitis and nausea/emesis 
G3 at 30 mg in one patient each) and two in schedule B (diarrhea and headache G3 at 40 
mg in one patient each). Four patients continued treatment after dose de-escalation. One 
patient was taken off study by investigator´s decision because of ECG alterations G1 after 
three doses of panobinostat; this patient was not evaluable for DLT and was replaced. The 
MTD for schedules A (weekly) and B (every other week) was determined to be 20 mg TIW 
and 30 mg TIW, respectively. 
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Safety  
All enrolled patients who received at least one dose of panobinostat were included in the 
safety analysis. Most patients (35 out of 42, 83%) experienced at least one G3/4 AE, which 
was judged to be panobinostat-related in 22 patients (52%) with no significant difference 
between schedules (schedule A: n=12, 57%; schedule B: n=10, 48%). However, 
panobinostat-related G4 hematologic toxicity and G1-3 constitutional symptoms were only 
observed in schedule A. All panobinostat-related G3/4 AEs are listed in table 2. G1/2 AEs 
were included only if they constituted a DLT or resulted in a modification of the panobinostat 
dose. Panobinostat-related AEs were fully and rapidly reversible after interrupting 
panobinostat, there were no study-related deaths and no patient died on treatment or within 
28 days of the last panobinostat dose. 
 
Thrombocytopenia is a well-recognized class effect of DACi. Platelet counts decreased 
significantly from baseline levels already by 8, i.e. after 3 doses of panobinostat in both 
schedules A and B (170±12 vs. 127±9/nL, n=42, mean ± SEM, p <0.001, paired samples t-
test). Thrombocytopenia was more pronounced with schedule A, increasing progressively 
until day 57 (146±15 vs. 71±7/nL, n=15, p <0.001) (figure 2). In schedule B, platelet counts 
recovered to baseline values by day 15 (195±22 vs. 195±19/nL, n=19, p=ns) and up to 40 
mg panobinostat was not associated with cumulative hematologic toxicity in schedule B. 
 
The most common G3/4 AEs irrespective of causality to study drug are listed in 
supplementary table 1. Twelve patients (29%) developed AEs that led to permanent 
discontinuation of the study drug after a median of 30 days (range, 7-293), including acute 
GvHD G3 (n=2), fatigue G3, relapse of lung cancer, pulmonary fibrosis, elevation of lipase 
G3 and ECG abnormalities (ST deviations).  
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Dose intensity and treatment duration  
Panobinostat was started a median of 96 days (range, 60-147) after HSCT. Twenty-two 
patients (52%) received panobinostat for one year as scheduled (A: 10/21 patients, 52% vs. 
B: 12/21, 57%). Besides AEs (n=12), reasons for prematurely discontinuating the study were 
relapse (n=5), patient decision (n=2) or prohibited comedication (n=1). Of the 27 patients 
treated at the MTD, 15 patients (55%) dropped out early after a median of 47 days (range, 
11-172) and additional 4 patients (15%) required reduction of the panobinostat dose. Median 
duration of treatment at the MTD was 52 days (range, 11-368) in schedule A and 228 days 
(16-365) in schedule B.  
 
 
Outcome 
 
To date, median OS and DFS have not been reached after a median follow up of 22 months 
(range, 6-57) (Figure 3). At two years after the first panobinostat dose, the CI of relapse and 
non-relapse mortality were 20% (95% CI, 7-33%) and 5% (95% CI, 0-11%, figure 4A) 
resulting in probabilities for 2-year OS and DFS of 81±7% and 75±7%, respectively. Ten 
patients died from relapse (n=6), sepsis (n=1), severe chronic GvHD (n=1), relapse of pre-
existing lung cancer (n=1) and sudden death (n=1; 3.5 months after study discontinuation), 
respectively.  
 
Concurrent donor lymphocyte infusions and panobinostat  
Only three out of 42 patients developed acute GvHD while on study (G1, n=1; G3, n=2). 
Donor lymphocyte infusions were not mandated by the study protocol but could be given 
optionally at the discretion of the treating physician. During panobinostat treatment, 18 
patients (43%) received a median of two DLI (range, 1-6) because of falling donor chimerism 
(n=6), detection of MRD (n=2) or prophylacticly (n=10). Prophylactic DLI were initiated at a 
median of 88 days (range, 49-317) after the first panobinostat dose and contained a median 
of 0.2x106 CD3+ cells/kg body weight, whereas preemptive DLIs were administered slightly 
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later (104 days, range, 50-231) at a higher starting dose of 0.9x106 CD3+ cells/kg. DLI were 
equally distributed between patients in both treatment schedules (43% of patients each). CI 
of moderate (n=10) or severe (n=2) chronic GvHD was 29% (95 CI, 16-42%) at two years 
after the first panobinostat dose and did not differ between both arms (Figure 4B).  
 
Reconstitution of immune cells 
Previous data have shown that the immune system is a critical component of the anti-tumor 
effects of DACi (33). Thus, peripheral blood samples were collected for prospective 
assessment of lymphocyte subpopulations from 26 out of 42 patients (62%) during study 
treatment. As detailed in figure 5A and B, CD4+ and CD8+ T cell counts improved over time 
and did not differ between study arms. The frequency of regulatory T cells, however, showed 
statistically significant differences for at least five months of panobinostat therapy with a 
higher proportion in schedule B (p<0.01, Figure 5D). The absolute cell count of regulatory T 
cells was also higher in schedule B, but not statistically significant (Figure 5C). NK cell 
recovery does not seem to be affected by panobinostat treatment with absolute NK cell 
values reaching the normal ranges of adult patients (103-760 cells/µl, Figure 5E). 
Importantly, B cells numbers increased significantly faster in schedule B during the first three 
months of panobinostat (p=0.001, Figure 5F). After one year, B cell values fell well within 
normal ranges (81-760 cells/µl).  
 
 
Discussion 
Maintenance therapy after allogeneic HSCT has become an area of evolving research 
activity, fostered by the dismal outcome of therapy for overt relapse after transplant (1). To 
date, few clinical trials have explored post-transplant intervention in AML, reflecting the still 
limited number of available agents combining anti-leukemic potential with a favourable 
toxicity profile. These properties are essential prerequisites for post-transplant maintenance 
therapy and are not met by conventional cytotoxic agents.  
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Our trial is one of only two trials examining a DAC inhibitor after HSCT (34) and the first 
completed prospective study assessing feasibility of prolonged post-transplant administration 
of a DACi as prophylaxis after HSCT for AML or any acute leukemia. The study hypothesis, 
that panobinostat would have a beneficial impact on post-transplant outcome by combining 
direct and immune-mediated antileukemic effects with suppression of GvHD, was based on 
results of early phase clinical trials in the non-transplant setting and on preclinical data (22). 
Phase I/II trials for relapsed or refractory AML or high-risk MDS suggested a dose-dependent 
response, but the MTD and RP2D determined in these trials subsequently proved to be 
incompatible with prolonged administration (20), (35), (36), (37). Moreover, tolerability and 
hematologic adverse events, most notably thrombocytopenia, differed by schedule of 
panobinostat administration (20). We therefore evaluated weekly and every other week 
schedules during dose-escalation to identify a panobinostat dose and schedule compatible 
with long-term administration. The MTDs defined as 20 mg TIW and 30 mg TIW with weekly 
and alternating week schedules, respectively, are in accordance with those identified in non-
transplanted patients requiring prolonged therapy, such as myeloma, for which panobinostat 
was recently approved as salvage therapy (38), as well as primary myelofibrosis or post-
polycythaemia vera / post- essential thrombocythaemia myelofibrosis (39).  
The degree of thrombocytopenia, fatigue and gastrointestinal toxicity that was observed 
favored the alternating week administration and resulted in a significantly higher cumulative 
dose delivered at the MTD by this schedule. Both of these AE categories are dose-
dependent class effects of DACi that have been observed in all disease entities studied and 
are not unique to the post-transplant setting. The early decline in platelets is likely due to 
defective maturation of megakaryoctes rather than long-term cytotoxic effects on 
megakaryopoiesis (40), (41), and was not associated with severe bleeding episodes with 
either panobinostat schedule in our study. Nevertheless, the alternating week schedule is 
likely to provide a bigger margin of safety in patients who often have low starting levels of 
platelets after HSCT. Hematotoxicity has also been a consistent finding with post-transplant 
administration of hypomethylating agents (42), (43), (44), although no direct comparison 
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between DACi and azacitidine or decitabine in terms of tolerability and toxicity after HSCT is 
available.  
Preliminary evidence for efficacy in our trial is very encouraging, with survival probability of 
81% at 2 years after starting panobinostat and a 20% cumulative rate of relapse at 2 years. 
These outcome data are even more remarkable considering that all AML patients were high 
risk by commonly accepted criteria (45) and the majority (67%) had active disease at the 
time of HSCT. Survival rates reported for such patient cohorts are extremely poor, with 
cumulative probability of relapse exceeding 30-60% at 2-3 years after HSCT (7), (6), (9). In 
view of our remarkably good outcome data, we have to consider the possibility of selection 
bias due to inclusion criteria requiring peripheral blood count recovery, adequate organ 
function and absence of clinically relevant acute or chronic GvHD. These criteria are typical 
of phase I trials but necessarily limit the risk for transplant-related mortality, which may have 
contributed to the very good survival. In addition, we permitted patient enrolment only 
between days 60 and 150 after HSCT, and not at the time of transplant because of the phase 
I/II nature of the trial. Although relapse risk was analysed as a time dependent variable, we 
cannot exclude that patients with extremely rapid disease kinetics are underrepresented, as 
the median time to relapse after HSCT is 4 to 6 months for high-risk AML (3), (46). 
Nevertheless, median time to enrollment after HSCT in our study was 3 months, which is 
less than the median time to relapse of 8 months reported in the RICAZA trial (43). 
  
Notably, the low relapse rate observed in the PANOBEST trial was not counterbalanced by a 
higher than expected incidence of clinically significant chronic GvHD even among patients 
receiving additional DLI, suggesting that panobinostat does not impair development of 
peripheral tolerance and may actually mitigate GvHD.  
Our data are in agreement with the only other phase I/II study of peri-transplant DACi that 
has been published to date, which investigated whether vorinostat reduces the risk of acute 
GvHD when administered together with standard immunosuppressive therapy during and up 
to 100 days after reduced-intensity conditioning (34). The incidence of grade 2-4 acute GvHD 
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was significantly lower compared to a historical patient cohort, and translational studies 
confirmed a vorinostat-mediated increase of regulatory T cells and FOXP3 and IDO 
expression, as previously described for pan-DACi (47), (48). Preclinical data indicate that 
these immunomodulatory effects of pan-DACi on Tregs may be dose-dependent (49). 
Whereas pan-DACi such as panobinostat at low doses primarily inhibit class I HDAC and 
exert regulatory T cells suppressive effects, higher doses predominantly target class II HDAC 
and promote regulatory T cells. Our study indeed demonstrates that the proportion of 
regulatory T cells decreases with schedule A, while remaining stable with the higher doses 
delivered during alternating week panobinostat in schedule B. Thus, in addition to 
determining tolerability, dosing of panDACi such as panobinostat may have profound clinical 
implications due to the dose-dependence of its effects on regulatory T cells. Schedule B  also 
seemed to be superior in promoting B cell recovery after HSCT, a potentially relevant finding 
considering recently reported B cell-mediated anti-tumor effects (50). In both our study and 
the trial of post-transplant vorinostat, immunomodulatory effects were not associated with a 
higher relapse rate, while possibly mitigating GvHD. In the setting of allogeneic HSCT, pan-
DACi may thus ameliorate alloreactivity while preserving an beneficial GvL effect. This 
concept is currently being evaluated in the setting of unrelated donor HSCT (NCT01790568).  
As regulatory T cell number and function are known to have opposing effects on GvL and 
GvHD, attention to dosing will be critical in future studies of post-HSCT use of pan-DACi. 
Conceptually, our study is most closely related to clinical trials investigating the role of 
hypomethylating agents in the post-transplant setting. Both drug classes represent 
epigenetic therapies and have well-recognized immunomodulatory properties, although no 
direct or comprehensive comparison of their activities has yet been conducted. To date, two 
prospective phase I/II trials have examined post-transplant maintenance with azacitidine in 
patients with AML or MDS (42) or AML only (RICAZA trial) (51), (43) one trial studied 
prophylactic decitabine in AML or MDS (44). Eligibility criteria and patient characteristics in 
the study performed by de Lima et al. were similar to our study, but no DLI were given. 
Median EFS and OS of the 45 patients who received azacitidine were encouraging, with 18.2 
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months and 30.8 months, respectively. In the RICAZA trial, 2-year OS and RFS probabilities 
were 81% (95 CI, 69-95%) and 49% (95% CI, 35-68%), respectively and median time to 
relapse was 8 months. In contrast to our study, most patients (32/37; 86%) were transplanted 
in CR rather than with active disease (43). The only study of decitabine maintenance after 
HSCT reported 2-year OS and EFS rates of 56% (95% CI, 38-83%) and 48% (95% CI, 30-
75%), respectively in 22 patients with HR-AML or MDS. As in the RICAZA study, most 
patients (64%) were in CR at the time of HSCT (44). In these three studies, only 20-43% 
patients received all scheduled cycles of HMAs, highlighting the difficulty of delivering 
maintenance therapy in the post-transplant setting.  
 
Taken together, the results of our study and available data from clinical trials of post-
transplant HMA support a prophylactic versus a pre-emptive strategy, particularly given the 
limited availability of highly sensitive and clinically validated MRD markers. We demonstrate 
that panobinostat as post-HSCT maintenance therapy for high-risk AML and MDS is feasible 
and associated with excellent survival. Longer follow-up and a prospective, randomized trial 
are needed to confirm the role of DACi maintenance after HSCT for high risk myeloid 
malignancies. 
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Figure legends 
 
 
Figure 1A. Study design. In phase 1, patients received escalating doses of panobinostat, 
initially administered three times per week (TIW) every week (Schedule A), a subsequent 
patient cohort received panobinostat in alternating weeks (Schedule B). In phase 2, patients 
were randomized to receive treatment with panobinostat either according to Schedule A or 
Schedule B, at the respective maximum tolerated dose (MTD) determined for each schedule. 
Time window for enrollment was 60 to 150 days after transplant.  Cond, conditioning; HSCT, 
hematopoietic stem cell transplantation 
 
Figure 1B: Patient allocation to administration schedule and dose levels. The first 
group of 12 patients (cohorts 1, 2 and 3) received panobinostat weekly at dose levels of 10 
mg, 20 mg and 30 mg TIW. Patients in cohorts 4, 5 and 6 received panobinostat during 
alternating weeks at dose levels of 20 mg, 30 mg and 40 mg TIW. In the expansion cohorts 
7A and 7B, an additional 9 patients in each schedule received panobinostat at the respective 
MTD. 
 
Figure 2: Platelet counts during study. Curves represent mean platelet counts for all 
patients treated in Schedules A and B, respectively, irrespective of dose level and starting 
with baseline counts. Error bars denote standard error of the mean (SEM).  
 
Figure 3. Survival analysis. Kaplan-Meier curves are shown for all patients enrolled, 
irrespective of treatment schedule or dose level and calculated from the first dose of 
panobinostat. Panel A: Overall survival; Panel B: Relapse-free survival. Symbols represent 
censoring times. Median follow up is 22 months (range, 6-57 months) 
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Figure 4. Panel A: Cumulative incidence (CI) of relapse and non-relapse mortality. Of 
all 42 patients enrolled, 9 relapsed and 5 died in complete remission (CR). At two years after 
starting panobinostat, the CI of relapse and non-relapse mortality were 20% (95% CI, 7-33%) 
and 5% (95% CI, 0-11%) respectively. Panel B:  The CI of moderate (n=10) or severe (n=2) 
chronic GvHD was 29% (95 CI, 16-42%) at two years after the first panobinostat dose and 
did not differ between both arms (Figure 4B).  
 
Figure 5: Reconstitution of immune cells 
Peripheral blood (PB) samples were prospectively collected at 6 timepoints (pre-treatment, 8, 
30, 90, 150 and 365 days after starting panobinostat) during the one year of study treatment 
for assessment of lymphocyte subpopulations. Data is available for 26 of 42 patients; the 
number of patient samples available for each timepoint is indicated by schedule. CD4+ T cell 
counts (Panel 5A) and CD8+ T cell counts (Panel 5B) did not differ between study arms. The 
absolute number of regulatory T cells was not statistically significantly different between 
schedules (Figure 5C), whereas the frequency of regulatory T cells (Treg) was significantly 
higher in patients treated according to Schedule B (Figure 5D). NK and B cell recovery are 
depicted in Figures 5E and 5F, respectively.  
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Table 1: Patient, disease and HSCT characteristics 
 
Schedule A 
(N=21) 
Schedule B 
(N=21) 
P value 
Median age, years (range) 58 (21-68) 50 (30-71) .351 
Sex 
male / female 
 
10 (48%) / 11 (52%) 
 
14 (67%) / (33%) 
.212 
Disease 
AML / MDS 
 
19 (90%) / 2 (10%) 
 
18 (86%) / 3 (14%) 
.634 
de novo 
secondary to MDS 
therapy-associated 
15 (72%) 
3 (14%) 
3 (14%) 
16 (76%) 
2 (10%) 
3 (14%) 
.890 
Karyotype (ELN criteria), AML only (n=37) 
good 
intermediate-1/-2 
adverse 
 
2 (10%) 
10 (53%) 
7 (37%) 
 
3 (17%) 
9 (50%) 
6 (33%) 
.859 
Stage prior to HSCT 
CR1/CR2 
primary refractory 
relapse 
untreated 
 
6 (28%) 
10 (48%) 
2 (10%) 
3 (14%) 
 
8 (38%) 
7 (33%) 
5 (24%) 
1 (5%) 
.404 
Median BM blasts at start of conditioning 
(range), n=28 
n=15 
20 (8-63) 
n=13 
23 (0-80%) 
.207 
Donor 
MRD / MMRD 
MUD / MMUD 
 
4 (19%) / 2 (10%) 
13 (61%) / 2 (10%) 
 
5 (24%) / 1 (5%) 
12 (57%) / 3 (14%) 
.877 
Conditioning regimens 
Fludarabine/Melphalan +/- BCNU 
Flamsa-RIC 
Fludarabine/Melphalan/TBI 2-8 Gy 
Fludarabine/TBI 2-8 Gy 
Fludarabine/Busulfan 
Other 
 
7 
5 
3 
2 
1 
3 
 
7 
3 
3 
3 
2 
3 
 
33% 
19% 
14% 
12% 
  7% 
14% 
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Abbreviations: ELN, European Leukemia Net; HSCT, hematopoietic stem cell 
transplantation; BM, bone marrow; MRD, matched related donor; MMRD, mismatched 
related donor; MUD, matched unrelated donor; MMUD, mismatched unrelated donor; 
Flamsa-RIC, fludarabine, amsacrine, AraC, reduced-intensity conditioning; TBI, total body 
irradiation; Gy, Gray;  
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Table 2: Adverse events considered related to panobinostat by treatment schedule and initial 
dose cohort 
Panobinostat-related 
toxicity 
Arm A, n (%) Arm B, n (%) 
G 1-2 G 3 G 4 G 1-2 G 3 G 4 
Blood /Bone marrow 0 6 (29) 2 (10) 0 7 (33) 0 
Cardiac 1 (5) 0 0 1 (5) 0 0 
Constitutional symptoms  
Fatigue 
Weight loss 
 
2 (10) 
1 (5) 
 
4 (19) 
0 
 
0 
0 
 
0 
0 
 
0 
0 
 
0 
0 
Gastrointestinal symptoms 
Nausea/Vomiting 
Diarrhea 
Colitis 
Anorexia 
Oral mucositis 
Taste alteration 
 
4 (19) 
3 (14) 
0 
1 (5) 
0 
0 
 
1 (5) 
1 (5) 
1 (5) 
0 
0 
0 
 
0 
0 
0 
0 
0 
0 
 
3 (14) 
1 (5) 
0 
0 
1 (5) 
1 (5) 
 
0 
2 (10) 
0 
0 
0 
0 
 
0 
0 
0 
0 
0 
0 
Pain 
Headache 
1 (5) 
0 
1 (5) 
0 
0 
0 
1 (5) 
0 
0 
1 (5) 
0 
0 
Renal failure 0 1 (5) 0 0 0 0 
Rash 0 0 0 1 (5) 0 0 
Sensory neuropathy 0 0 0 0 1 (5) 0 
Metabolic/Laboratory 
Elevated liver function tests  
Creatinine increased 
Hyperuricemia 
 
0 
1 (5) 
0 
 
0 
0 
1 (5) 
 
0 
0 
0 
 
2 (10) 
0 
0 
 
2 (10) 
0 
0 
 
0 
0 
0 
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Figure 1A 
Figure 1B 
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Figure 2  
 
 31 
Figure 3A: Overall Survival    B: Relapse-free survival 
 
 
 
Figure 4A: Relapse and non-relapse mortality          B: Moderate and severe chronic GvHD 
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Figure 5 
 
 
 
 
 
A B 
E F 
D C 
ARM A    15     16       15         12            8            10 
ARM B    10       8         9           9            6              5 
